CGP 28014

Drug Profile

CGP 28014

Latest Information Update: 19 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antidepressants; Antiparkinsonians; Neuroprotectants; Nootropics
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 19 Jul 2010 Discontinued - Phase-I for Parkinson's disease in Germany (PO)
  • 19 Jul 2010 Discontinued - Phase-I for Parkinson's disease in Switzerland (PO)
  • 13 Sep 1995 Suspended-I for Parkinson's disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top